Bridgebio Pharma, INC

BridgeBio Pharma announced the FDA has accepted its New Drug Application for encaleret to treat Autosomal Dominant Hypocalcemia Type 1 (ADH1), with a PDUFA target action date of May 8, 2027.

BridgeBio Pharma announced a $1 billion preferred equity financing led by Sixth Street and HealthCare Royalty to fund upcoming product launches and growth initiatives.

BridgeBio Pharma shareholders approved all proposals at the 2026 Annual Meeting, including an increase in shares for the incentive plan.

BridgeBio Pharma announced the FDA has accepted its New Drug Application for BBP-418 with Priority Review for LGMD2I/R9, setting a target action date of November 27, 2026.

BridgeBio Pharma, Inc. announced an at-the-market equity offering program to sell up to $500 million of its common stock.

BridgeBio Pharma reported strong Q1 2026 revenue growth driven by Attruby, alongside a new $500 million stock repurchase program authorization.

BridgeBio Pharma's Q1 2026 results show significant revenue growth driven by product sales, alongside increased operating expenses and continued net losses.

BridgeBio Pharma reports significant revenue growth in Q3 2025 driven by strong Attruby sales and strategic licensing milestones, despite continued net losses.

BridgeBio Pharma reported increased net product revenue from its newly approved therapies, Attruby and Beyonttra, but also a significant rise in net losses for the first half of 2025.

BridgeBio Pharma's Q1 2025 results highlight the successful commercial launch of Attruby and Beyonttra, alongside strategic financial maneuvers including a $575 million note issuance and debt repayment.

BridgeBio Pharma's Q3 2024 results show a significant increase in revenue due to licensing agreements, but the company expresses substantial doubt about its ability to continue as a going concern.

BridgeBio Pharma's Q2 2024 results include a significant gain from the deconsolidation of a subsidiary and updates on strategic licensing agreements and financing activities.

BridgeBio Pharma, Inc. reports significant commercial uptake for Attruby and positive Phase 3 clinical trial results for multiple pipeline candidates, despite continued net losses.

BridgeBio Pharma's 2024 10-K filing highlights the FDA approval of Attruby, its commercial launch, and advancements in its clinical pipeline.

BridgeBio Pharma's 2023 10-K filing highlights the company's progress in developing transformative medicines for genetic diseases and cancers, while navigating financial strategies and regulatory pathways.

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc., sold 2,000 shares of common stock on July 30, 2026 for $80.06 per share.

Andrea Ellis, a Director of BridgeBio Pharma, Inc., sold 17,167 shares of common stock on July 9, 2026 for $84.00 per share.

Jennifer E. Cook, a Director of BridgeBio Pharma, Inc., sold 148,589 shares of common stock on July 9, 2026.

Director Jennifer E. Cook reported transactions involving BridgeBio Pharma, Inc. common stock, including the acquisition of restricted stock units and the sale of shares under a 10b5-1 plan.

BridgeBio Pharma Director Hannah Valantine reported transactions involving common stock and stock options on June 22, 2026, including a grant of restricted stock units and sales under a 10b5-1 plan.

BridgeBio Pharma, Inc. reports a Form 4 filing detailing the acquisition of restricted stock units and stock options by Director Andrew Lo.

BridgeBio Pharma, Inc. has filed its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation proposals.

BridgeBio Pharma files a supplement to its proxy statement, seeking stockholder approval for an amended stock option plan and an officer exculpation provision at its upcoming annual meeting.

BridgeBio Pharma, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

BridgeBio Pharma is holding its annual meeting on June 20, 2025, to vote on director elections, executive compensation, auditor ratification, and amendments to its stock option plan and corporate charter.

BridgeBio Pharma has filed a definitive proxy statement with the Securities and Exchange Commission.

BridgeBio Pharma is asking stockholders to approve an amendment to its 2021 Stock Option and Incentive Plan, primarily to increase the number of shares available for issuance by 6,500,000.

Viking Global Investors LP and affiliated entities have reported significant sales of BridgeBio Pharma, Inc. common stock, reducing their beneficial ownership below 5%.

Viking Global Investors LP and affiliated entities have filed an amendment to their Schedule 13D, reporting a change in beneficial ownership of BridgeBio Pharma, Inc. common stock.

Viking Global Investors and its affiliates have reduced their beneficial ownership in BridgeBio Pharma, Inc. to 8.2% through recent stock sales.

Viking Global Investors LP and affiliates updated their beneficial ownership in BridgeBio Pharma, Inc., reporting a net reduction in shares since July 1, 2025.

Viking Global Investors and its affiliated entities have filed an Amendment No. 7 to their Schedule 13D, reporting a reduced beneficial ownership of 9.8% in BridgeBio Pharma, Inc. following significant net selling of shares.

KKR Genetic Disorder L.P. has filed an amendment to its Schedule 13D, disclosing the sale of 6 million shares of BridgeBio Pharma, Inc. common stock for $34.20 per share, reducing its beneficial ownership to 7.0%.

Farallon Capital Management, L.L.C. and its affiliates have reported beneficial ownership of 5.5% of BridgeBio Pharma, Inc.'s common stock as of June 30, 2026.

Farallon Capital Management and its affiliates have reported a 5.2% beneficial ownership stake in BridgeBio Pharma, Inc.

Janus Henderson Group plc has reported beneficial ownership of 13,179,013 shares, representing 6.8% of the outstanding common stock of BridgeBio Pharma, Inc.

Dr. Neil Kumar filed an amendment to his Schedule 13G, disclosing a 4.6% beneficial ownership stake in BridgeBio Pharma, Inc. as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Bridgebio Pharma Inc. following an internal realignment.

Janus Henderson Group plc has reported a 5.7% beneficial ownership stake in BridgeBio Pharma, Inc., holding over 11 million common shares.